chufangao/CTO huggingface dataset:
Clinical trial NCT05224856: To Evaluate the Safety and Efficacy of Inhaled CT-P63 and CT-P66 Combination Therapy in Symptomatic Patients With COVID-19 Not Requiring Supplemental Oxygen
Official title: A Phase 3, Randomized, Parallel-group, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Inhaled CT-P63 and CT-P66 Combination Therapy in Symptomatic Patients With Coronavirus Disease 2019 (COVID-19) Not Requiring Supplemental Oxygen
Sponsor: Celltrion (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: The sponsor has decided to stop development of the inhaled CT-P63/66 combination therapy.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-04-30
Primary completion date: 2022-11-30
Completion date: 2023-01-31
Plan to share individual participant data: NO
Clinical trial NCT05208866: Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303
Official title: PA-ADPKD-304: A Phase 3, Open-label, Roll-over Study to Assess Long-term Safety of Lixivaptan in Participants With Autosomal Dominant Polycystic Kidney Disease Who Completed Study PA-ADPKD-303: The ALERT Study
Sponsor: Palladio Biosciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The decision is based on a thorough reassessment of the commercial potential of lixivaptan as a potential best-in-class therapy for patients with ADPKD.
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-02-10
Primary completion date: 2022-06-29
Completion date: 2022-07-29
Baseline population: Since only one participant completed the study, due to confidentiality issues, no data will be reported.
Limitations and caveats: Efficacy and safety results are limited by the early termination of the trial and the small number of subjects. Early termination was due to a sponsor decision for reasons unrelated to safety.
Plan to share individual participant data: NO
Clinical trial NCT04676126: Augmented Macular Pigment-containing Nutraceutical and Central Visual Function
Official title: Augmented Macular Pigment Supplement and Pericentral Visual Function: a Randomized Controlled Trial
Sponsor: University of the Incarnate Word (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: IRB records show administrative closure on 12/16/21. No subjects enrolled.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-05-31
Primary completion date: 2022-05-31
Completion date: 2022-05-31
Plan to share individual participant data: NO
IPD sharing description: There is no plan to share IPD to other researches.
Clinical trial NCT02347891: Belimumab in Idiopathic Inflammatory Myositis
Official title: Belimumab for Maintenance Therapy in Idiopathic Inflammatory Myositis
Acronym: BIM
Sponsor: Northwell Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 17.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-01-31
Primary completion date: 2020-11-30
Completion date: 2020-11-30
Baseline population: 29 screened, 19 enrolled, 2 withdrew consent before randomization. 17 patients started the trial and were randomized. Of 17 patients randomized, 15 received at least 5 doses of belimumab or placebo and were included in the final intention-to-treat analysis. 14 patients (8/9 in the belimumab arm and 6/7 in the placebo arm) completed all 40 weeks of randomized phase. Seven (7/9) patients from belimumab arm and 5 (5/7) from placebo arm completed 24 weeks of open label extension with IV belimumab.
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02945644: Trazodone Dose Tolerance and APAP Adherence
Official title: Randomized Controlled Trial of Trazodone Dose Tolerance and APAP Adherence
Acronym: TrazoDose
Sponsor: Louis Stokes VA Medical Center (FED)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: SUSPENDED 
Why stopped: COVID19 pandemic
Enrollment: 45.0 (ESTIMATED)
Number of arms: 3.0
Start date: 2017-02-13
Primary completion date: 2020-09-30
Completion date: 2020-12-31
Plan to share individual participant data: NO
Clinical trial NCT05737186: SGLT2 Inhibitors and Treatment of Heart Failure in Severe Renal Insufficiency
Official title: The Efficacy and Safety of SGLT2 Inhibitors in Improving Heart Failure in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) and Severe Renal Insufficiency
Sponsor: Peking University People's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Double blind packaged drug is up to expiration date
Enrollment: 11.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-03-09
Primary completion date: 2024-04-16
Completion date: 2024-04-16
Clinical trial NCT04853147: Triple Therapy for Postoperative Nausea and Vomiting in Laparoscopic Gastrointestinal Surgery
Official title: Triple Combination of Fosaprepitant, Dexamethasone and Palonosetron Versus Combination of Dexamethasone and Palonosetron for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Gastrointestinal Surgery
Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1154.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-27
Primary completion date: 2022-04-13
Completion date: 2022-10-12
Plan to share individual participant data: NO
Clinical trial NCT04460885: A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before
Official title: A 78-week Trial Comparing the Effect and Safety of Once Weekly Insulin Icodec and Once Daily Insulin Glargine 100 Units/mL, Both in Combination With Non-insulin Anti-diabetic Treatment, in Insulin naïve Subjects With Type 2 Diabetes
Acronym: ONWARDS 1
Sponsor: Novo Nordisk A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 984.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-25
Primary completion date: 2022-05-29
Completion date: 2022-12-01
Plan to share individual participant data: YES
IPD sharing description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Clinical trial NCT05999708: A First Time in Human Study to Evaluate the Safety and Tolerability of GSK4381406 in Healthy Participants
Official title: A Randomized, Double-Blind, Placebo-Controlled, Single, Repeat Dose Escalation and Indomethacin Challenge Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK4381406 in Healthy Participants
Sponsor: GlaxoSmithKline (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Study terminated prior to FSFV for strategic business reasons.
Enrollment: 0.0 (ACTUAL)
Number of arms: 8.0
Start date: 2023-10-31
Primary completion date: 2024-12-05
Completion date: 2024-12-05
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
IPD time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
IPD access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Clinical trial NCT02703272: A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
Official title: A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: IDMC recommended that enrolment be stoped, as the EFS hazard ratio and associated p-value crossed the futility boundary specified in protocol (July 2020).
Enrollment: 72.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-07-01
Primary completion date: 2021-06-11
Completion date: 2021-06-11
Clinical trial NCT03917472: Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
Official title: A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KINGFISHER)
Acronym: KINGFISHER
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 517.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-07-17
Primary completion date: 2021-03-24
Completion date: 2021-03-24
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of the patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT03389490: Toujeo Versus NPH Self-titration Study
Official title: A Pilot Study to Describe the Glycaemic Variability of Insulin Glargine 300U/ml Versus NPH (Neutral Protamine Hagedorn) in the Insulin-naïve Type 2 Diabetes Patients Following a Patient-adjusted Insulin Algorithm in Hong Kong
Sponsor: Chinese University of Hong Kong (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 50.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-01-01
Primary completion date: 2019-12-17
Completion date: 2020-05-01
Plan to share individual participant data: NO
Clinical trial NCT04325698: A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC
Official title: A RANDOMIZED, DOUBLE-BLIND BRIDGING SAFETY AND EFFICACY STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN FOR THE FIRST-LINE TREATMENT OF CHINESE PARTICIPANTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The study was terminated as part of the decision by Pfizer to halt its biosimilars programs in China.
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-11
Primary completion date: 2021-05-10
Completion date: 2021-05-10
Limitations and caveats: The study was terminated on 17 March 2021 by the Sponsor. The decision to terminate this study was based on a business review of the biosimilars market and the Sponsor's global manufacturing network. This decision was not based on any safety or regulatory concerns with the treatment of participants with PF-06439535 (CN). The results reported are limited to safety, PK and immunogenicity, and only safety is summarized.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT04855201: A Study to Evaluate ASP0367 in Participants With Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction
Official title: A Phase 1b Multiple Oral Dose Study to Evaluate the Pharmacological Effect, Safety and Tolerability of ASP0367 in Participants With Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction
Sponsor: Astellas Pharma Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Lack of Pharmacological effect
Enrollment: 31.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-06-14
Primary completion date: 2022-12-16
Completion date: 2022-12-16
Plan to share individual participant data: NO
IPD sharing description: Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under Sponsor Specific Details for Astellas.
Clinical trial NCT05241470: Study of ST-100 as Treatment for Dry Eye Disease
Official title: A Phase 2 Multi-Center, Randomized, Double Masked, Placebo Controlled Study to Assess the Safety and Efficacy of ST-100 Ophthalmic Solution in Subjects Diagnosed With Dry Eye Disease
Sponsor: Stuart Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 160.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-05-17
Primary completion date: 2021-10-11
Completion date: 2021-10-11
Plan to share individual participant data: NO
Clinical trial NCT03104400: A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
Official title: A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1
Acronym: SELECT - PsA 1
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1705.0 (ACTUAL)
Number of arms: 5.0
Start date: 2017-04-27
Primary completion date: 2019-09-26
Completion date: 2024-09-09
Baseline population: The full analysis set included all randomized participants who received at least 1 dose of study drug.
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Clinical trial NCT02039726: (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
Official title: A Phase 3 Open-label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects With Tyrosine Kinase 3 - Internal Tandem Duplication (FLT3-ITD) Positive Acute Myeloid Leukemia (AML) Refractory to or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation
Sponsor: Daiichi Sankyo (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 367.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-05-31
Primary completion date: 2018-02-22
Completion date: 2020-09-08
Baseline population: Participants received standard of care salvage chemotherapy (administered subcutaneously \[LoDac\] or intravenously \[MEC and FLAG-IDA\]).
Plan to share individual participant data: YES
IPD sharing description: De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
IPD time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
IPD access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Clinical trial NCT05945160: Vestibular Function Using Mitochondrial Antioxidant Therapy
Official title: A Randomized Controlled Study Using Alpha Lipoic Acid and CoQ-10 to Determine if Vestibular Function Can be Improved or Maintained Over the Course of One Year
Sponsor: The University of Texas Health Science Center at San Antonio (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Funding was terminated, the study will not enroll any subjects
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2024-01-31
Primary completion date: 2024-08-31
Completion date: 2024-12-31
Plan to share individual participant data: YES
IPD sharing description: All collected deidentified IPD that underlie results in a publication
IPD time frame: At study completion when the PI publishes in a peer review journal.
Clinical trial NCT04395092: Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)
Official title: Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)
Sponsor: Kiadis Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: The sponsor decided to withdraw this study
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-11-13
Primary completion date: 2022-11-30
Completion date: 2023-11-30
Plan to share individual participant data: NO
Clinical trial NCT04851522: Dilute Bleach Compresses for Radiation Dermatitis
Official title: The Impact of Dilute Bleach Compresses on the Incidence and Severity of Radiation Dermatitis
Sponsor: Dana-Farber Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Lack of patient accrual in the past year.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-06-09
Primary completion date: 2022-04-01
Completion date: 2023-04-01
Plan to share individual participant data: YES
IPD sharing description: The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: \[contact information for Sponsor Investigator or designee\]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
IPD time frame: Data can be shared no earlier than 1 year following the date of publication
IPD access criteria: Contact the Technology \& Innovation Development Office at www.childrensinnovations.org or email TIDO@childrens.harvard.edu Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu
Clinical trial NCT01472562: Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma
Official title: Phase II Study of Lenalidomide Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
Sponsor: Weill Medical College of Cornell University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 38.0 (ACTUAL)
Number of arms: 1.0
Start date: 2011-07-29
Primary completion date: 2014-04-30
Completion date: 2023-07-30
Clinical trial NCT03118674: Harvoni Treatment Porphyria Cutanea Tarda
Official title: Newer Direct-Acting Anti-Viral Agents as Sole Therapy of Porphyria Cutanea Tarda in Subjects With Chronic Hepatitis C
Sponsor: Wake Forest University Health Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 23.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-09-06
Primary completion date: 2022-03-04
Completion date: 2022-03-04
Baseline population: Participants that started treatment
Limitations and caveats: We were not able to recruit as many subjects as we had originally planned and hoped to enroll \[original target n = 49\].
Plan to share individual participant data: NO
Clinical trial NCT03701698: Ruxolitinib and Steroid As First Line Therapy for Acute GVHD
Official title: Ruxolitinib and Methylprednisolone As First Line Therapy for Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Participants recruitment failure
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-11-01
Primary completion date: 2024-09-20
Completion date: 2024-09-20
Clinical trial NCT05008445: Study of LM-102 in Patients With Advance Solid Tumors
Official title: A Phase I/II, Open-Label, Multiple Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-102 Monotherapy or Combination Therapy in Patients With CLDN18.2-Positive Advanced Solid Tumors
Sponsor: LaNova Medicines Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: company adjusted strategy
Enrollment: 11.0 (ACTUAL)
Number of arms: 7.0
Start date: 2021-10-06
Primary completion date: 2023-02-08
Completion date: 2023-02-28
Plan to share individual participant data: NO
Clinical trial NCT04683939: Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
Official title: Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT141 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With CLDN18.2-positive Solid Tumors
Sponsor: BioNTech SE (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 13.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-01-18
Primary completion date: 2023-07-24
Completion date: 2023-07-24
Baseline population: Safety Set - All patients who received investigational medicinal product (IMP) (i.e., at least one dose of BNT141)
Plan to share individual participant data: NO